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Abstract
Data are more valuable than scientific papers but researchers are incentivised
to publish papers not share data. Patients are the main beneficiaries of data
sharing but researchers have several incentives not to share: others might use
their data to get ahead in the academic rat race; they might be scooped; their
results might not be replicable; competitors may reach different conclusions;
their data management might be exposed as poor; patient confidentiality might
be breached; and technical difficulties make sharing impossible. All of these
barriers can be overcome and researchers should be rewarded for sharing
data. Data sharing must become routine.
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Good, well curated data are more valuable than the words authors 
write about them, but until now the main currency of science has 
been publications. With the World Wide Web sharing and publish-
ing data is now possible, and researchers should be rewarded for 
doing so. Authors unfortunately have incentives not to share data 
and continue to find excuses for not doing so – but the excuses are 
poor. It’s time for data sharing to become routine.
The value of data
Datasets are more valuable than papers because: they allow analy-
ses to be replicated helping to avoid error, selective reporting and 
fraud; they can be used to answer other research questions; and 
they facilitate methodological research and the teaching and 
training of researchers. Papers, in contrast, rarely report the full 
data and are often “spun” to present results that flatter authors and 
please editors.
Patients are the main beneficiaries of data sharing
The main beneficiaries of sharing data are patients, the people who 
as taxpayers fund most research. They clearly have an interest in 
both the right conclusion being reached and in maximum value 
being squeezed from every dataset. Unfortunately many others in 
the research system do not have the same interest in the “truth.”
If we consider a clinical trial or indeed any study with clinical 
implications then the prime interest of the patients is that the results 
are “true” and that clinicians use them to improve their well-being. 
This means that the analyses should be accurate and replicable. 
Sadly the producers of research have interests apart from truth: 
researchers want high impact papers; universities want the same 
and lots of publicity too; editors and publishers want “good” 
publications that increase their impact factor; and funders want to 
show “value for money,” which may means lots of publications 
regardless of their truth. Nobody is incentivised to share data, rep-
licate results, and perhaps show the weak underbelly of science, 
which is why the scientific community has responded so poorly to 
allegations of misconduct1.
By participating in clinical research patients make a gift to others, 
rather as those who give blood do. They and their gift, their data, 
should be treated with reverence. Their gift is not for individual 
researchers to use to advance their careers but for the wider scien-
tific community and other patients. Their gift must be shared.
The seven incentives not to share
Because they are measured primarily by how much and where they 
publish, researchers are strongly incentivised to publish, preferably 
in high impact journals. There are not the same incentives to share 
data. Indeed, there are seven incentives (or excuses) not to share.
Firstly, data are the base for research articles, and one anxiety for 
researchers is that others will use their data to produce publications 
without having to go to the trouble of gathering them. They will 
be disadvantaged in the academic rat race, although if everybody 
shared data they could benefit from using data from others.
Secondly, other researchers might scoop them, perhaps even prevent 
them from achieving publication in a high impact journal. Funders 
who require data sharing have responded to the anxiety of being 
scooped by allowing researchers to delay sharing their data. A 
better response would be to move away from “outsourcing” the 
judgement of the performance of researchers to publishers and 
for employers and funders to recognise that judging researchers 
is core business that should not be outsourced to the arbitrary and 
corrupted publishing process.
A third reason for not sharing data is a fear held by researchers that 
their conclusions will not be replicable. This is an ignoble reason 
because replicability is central to science. Some scientists may fear 
replication because they repeat experiments day after day and publish 
them only when they become “right.” This is unscientific and can 
lead to serious defects in the scientific evidence base.
One of us (IR) has made data from two large clinical trials avail-
able in the hope that somebody will replicate the analysis and 
confirm (or fail to confirm) the results (https://ctu-app.lshtm.ac.uk/
freebird/)2,3. Although the data have been used to answer many dif-
ferent questions, there has been no replication of the original trial 
results, probably because there is no incentive to do so - there ought 
to be. It surely makes economic sense for the millions spent on the 
trial to be backed up by the few thousands that would be needed 
to encourage replication. We hope that somebody will take up the 
challenge.
A fourth reason researchers may want to keep their data to them-
selves is to avoid their critics analysing the data and coming up 
with different or contrary results. Statisticians say that “if you torture 
the data they will confess,” but refusing to release data hands a vic-
tory to critics who will inevitably say “the researchers obviously 
have something to hide, they can’t support their conclusions.” 
Uncomfortable as it may be, it’s a better and more scientific strategy 
to enter “the market of ideas” and expect to show the correctness of 
your analysis and conclusions.
There is a legitimate worry about releasing data when researchers 
fear they may be sued. The problem here is that a battle in court is 
not a battle of evidence and data but a battle of showmen with a 
highly uncertain outcome. This is not a worry with most datasets, 
and perhaps when it is the data can be released in exchange for a 
legally binding commitment not to sue.
The authors of a major trial that showed the ineffectiveness of 
hydroxyethyl starch solutions for fluid resuscitation have declined 
to share their data4,5. They say that there have been “repeated efforts 
to discredit” by critics who want “to protect their commercial 
interests.” The authors have declined even to allow a reanalysis by 
a third party. This cannot be in the interest of patients, who clearly 
want to know whether the treatment is ineffective or not, but the 
authors may have a legitimate worry about legal action.
The fifth and perhaps worst reason for not releasing data is that 
data management is often poor and sharing the data may expose 
horrible weaknesses, flaws, and inconsistencies in the data. Sadly 
this may be the commonest but least declared reason for not sharing 
data. That some universities dedicate more resources to media rela-
tions than research governance is disturbing but not surprising. 
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Making a big splash in the news can bolster grant income and student 
recruitment even when the informational content of the research is 
doubtful.
A sixth excuse for not sharing data that is available to those who 
do research with patients is patient confidentiality. One case of 
private information of a patient being exposed could, some 
researchers argue, bring data sharing to a halt. It is a “never event” 
that must be avoided even if huge benefits are foregone by not 
sharing data. Patient confidentiality must be guarded, and most of 
the time it’s easy to do so by anonymising data and removing data 
on, for example, place and time. It’s true that small risks remain 
because of rare conditions and events and because of “jigsawing” 
(combining datasets to break confidentiality), but these small risks 
can be explained to patients, who will almost always consent 
to their data being made available in anonymous form. With 
datasets that are already collected patients might be asked to give 
retrospective consent.
Patient confidentiality is the reason that authors of a controver-
sial trial on treatment of chronic fatigue syndrome give for not 
sharing their data, but inevitably they look as if they are hiding 
something6,7.
The final and probably weakest excuse researchers give for not 
sharing data is “technical reasons.” But this is a lame excuse—
other areas of science—for example, physics, astronomy, and 
engineering—have shared datasets far larger and more complex 
than those produced in biomedical research. There are no insur-
mountable technical reasons to sharing and publishing data.
Reward authors for sharing data
Researchers should be rewarded not for publications but for produc-
ing large amounts of high quality data. Papers are a poor measure 
of the quantity or quality of research data. In terms of papers, a 
trial with 100 patients is the same as one with 10 000 patients, 
even though the informational content of the latter is 100 times the 
former. And despite the reverence for peer review, data quality is 
remarkably hard to judge from publications.
Funders of research and employers of researchers need to change 
the incentives for researchers to encourage data sharing, but 
researchers must also recognise the weakness of their excuses and 
contribute to the big advance in science that can come from sharing 
and publishing data.
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doi:10.5256/f1000research.9066.r14294
 Gustav Nilsonne
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
This opinion piece describes and refutes seven arguments against sharing research data. The authors
focus on clinical trials, but their reasoning is applicable to research with human participants in general.
In the ongoing conversation about open research data in scientific journals, arguments against open data
are not always presented clearly and explicitly. The mere listing of counterarguments in a paper that can
be referenced is therefore an important contribution.
The authors refute each argument against data sharing in a clear and coherent manner and their
counterarguments are a valuable resource for researchers debating open data.
I have only one minor point of criticism: the statement in the last paragraph that a study with 10 000
participants has 100 times more information content than a study with 100 participants does not take into
account the diminishing information content in consecutive dependent observations. I suggest this may
be reworded.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 I am currently chairperson of the Open Badges committee at the Center for OpenCompeting Interests:
Science, which works to incentivise data sharing.
 13 May 2016Referee Report
doi:10.5256/f1000research.9066.r13824
 Heather M Goodare
Edinburgh Health Forum, Edinburgh, UK
Thank you for asking me to comment on this paper.   I can only speak from the point of view of patients
and carers. 
 
The main problem is that of confidentiality of data, and some patients are worried about this.  The authors
acknowledge that this could be a problem (a sixth excuse).  Anonymising data is of course essential, but
'small risks remain'.  Remember the case of the anonymous male with back problems who was written
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'small risks remain'.  Remember the case of the anonymous male with back problems who was written
about in an American medical journal and turned out (without too much detective work) to be President
Kennedy?  Personally I don't care tuppence who knows that I have had breast cancer - it's in the public
domain anyway.  But some conditions people would not wish to be known about: abortions, STD, some
mental illnesses, and so on.  If data are anonymised that is usually sufficient safeguard, but in
epidemiological studies unique postcodes are a giveaway.
 
I am a member of the Public Panel of the FARR Institute in Scotland, and we have debated the matter of
Big Data at length.  We have a system here called SHARE, where if you are happy for your data to be
used for research you sign a form, obtainable from your GP's surgery.  This also gives permission for the
residue of blood samples taken for routine purposes to be used for research.  Most people are happy, but
some are not, even given the guarantee of anonymity. 
 
However, this system gives permission for data culled from healthcare registries to be used for research:
it does not as far as I know include data from trials already conducted.  This to me is a new idea, and it
raises different issues.
 
FARR talks about 'safe havens' for data, so that personal details cannot be shared and anonymity is
guaranteed.  It seems to me that if data already gathered for research are to be released to researchers
other than the original investigators, this raises an entirely new issue.  It would mean that consent forms
should be revised so that they take account of the possibility that data will be shared with others at a later
date. 
 
It is important to make it clear that healthcare data are not the property of the researchers who have only
borrowed them: they belong to the patient.  Therefore, if data are to be made more widely available, the
patient needs to give consent.  This means that consent forms need to make this explicit, and all other
data used for research, for instance epidemiological studies that do not require active co-operation from
the patient, need to have blanket consent from patients, who should be encouraged to complete a
SHARE form.
Personally, I like to know what researchers are going to do with my data.  My husband and I were
‘consulted’ as members of a patient reference group about a stroke trial (he has had a stroke), and we
both felt that it should not have gone ahead: the rest of the patient group thought so too, but it went ahead
anyway.  I don’t know how it got through Ethics.  The relevance for this paper is that patients do have a
right to say what their data are going to be used for.  If they don’t approve of the trial, then they won’t let
their data be used.  If they have given permission initially for a study that they approve of, and the
proposal is to share the data further, should they not be given a say in what their data are to be used for
subsequently?  Once Big Pharma get their hands on the data who knows what will become of it.
 
This makes the sharing of data more complicated, but I believe it should be done, and that this article
needs to take account of these issues.
I also have some minor copy-edit suggestions:
 
Abstract: “[…]competitors  reach different conclusions[…]”might
 
The seven incentives not to share: “[…]for employers and funders to recognise that judging
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The seven incentives not to share: “[…]for employers and funders to recognise that judging
researchers is core business that should not be outsourced to the arbitrary and  publishingcorrupt
process.”
 
The seven incentives not to share: “This cannot be in the interest of patients, who clearly want to
know whether the treatment is  or not […]”effective
 
The seven incentives not to share: “There are no insurmountable technical reasons sharingfor not 
and publishing data.”
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
 05 May 2016Referee Report
doi:10.5256/f1000research.9066.r13665
 Thomas Walley
Department of Health Services Research, University of Liverpool, Liverpool, UK
Data sharing has been an expectation and indeed a contractual obligation for all research funded by
NIHR, the research arm of the NHS, for many years. This has meant that bona fides researchers can
request access to study data for defined proposes and with a suitable protocol, which should not be
unreasonably withheld, e.g. for purposes of IPD meta-analysis. This is not open but controlled access to
the data. The arbiter of what is reasonable access to the data falls to the researcher in the first instance,
then to his/her host institute, but ultimately to the funder who held the contract.  
The recent consultation from the ICMJE (  willhttp://www.nejm.org/doi/full/10.1056/NEJMe1515172
probably translate into a requirement that data sets be made available in a more transparent way, usually
by host institutions, in some form of as yet undefined registry.
Why not open access? Smith and Roberts consider some of these issues:
Ownership of the data: this (and responsibility for curation and archiving) rests with the institute but
subject to the terms of the contract. Inevitably however, a researcher will feel a degree of proprietary
protectiveness towards data sets. Most of us are not as altruistic in this regard as Smith and Roberts
would like. Given the incentives that exist in academia, some respect for the intellectual property that the
researcher has created is inevitable, and usually an agreement to access the data either in collaboration
or with due acknowledgement is an acceptable outcome for all.
Risks of confidentiality: many studies are not of the 20000 patients size that Roberts has made available:
smaller studies, with geographically defined recruitment may mean that the patient is potentially
identifiable, especially if complex sets of data – often collected in smaller studies but less likely in larger -
can also be accessed. Regrettably, there are people who seem to thrive on breaking open data like this: I
think that patient confidentiality requires us to ensure that the data remains anonymous, best achieved by
limited rather than open access.
Page 6 of 9
F1000Research 2016, 5:781 Last updated: 13 JUN 2016
F1000Research
Poor data handling: making data available to others is not without substantial cost, at a time when most
researchers are planning to move on to another study: e.g. labelling the files from complex data sets in
clear manner understandable to those who have not lived and breathed it for several years. Hence
collaborative access is an easier and less expensive solution, where possible. Archiving the data also
poses problems – who will take responsibility for converting data from old systems or software.
NIHR have established a contractual obligation, but like most other funders, has not yet provided the level
of funding to make this possible (except on one occasion to Roberts), nor a vehicle similar to the GSK-led 
 to facilitate this.clinicalstudydatarequest.com
None of this is to argue against the principles that Smith and Roberts put forward, but only to point out that
achieving their worthy aims will not be easy or as quick as it might seem. NIHR like other funders continue
to work to support this aim. As part of this, the NIHR journals library is also considering what constitutes
publication: perhaps a somewhat selective journal article, a detailed monograph as has been our practice
( ) or in the future, such a document with access to the data. Thesewww.journalslibrary.nihr.ac.uk
questions will not be quickly solved, and need much more debate to which this article by Smith and
Roberts is a valuable contribution
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 I have framed this from an NIHR perspective and work for NIHRCompeting Interests:
Author Response (  ) 10 May 2016F1000Research Advisory Board Member
, Patients Know Best Ltd, UKRichard Smith
I’m grateful to Tom for giving a rapid and useful on our paper. No doubt he is right that it will take a
longer time than we would like for data sharing to become routine.
Incentives are fundamental. At the moment incentives reward keeping data, but we must change
the incentives. We argue that the data are more valuable than the papers that arise from them, and
so funders of research should be thinking hard about how to reward the production of high quality
data. At the moment huge value is being lost from data being locked away, and data have a longer
lifespan than papers. At the very least funders should be willing to meet the costs of data sharing
that Tom identifies.
The confidentiality risk is, I fear, exaggerated. The obvious response is for researchers to get
consent from participants for data to be shared at the same time as minimising the risk of
exposure. It used to be that doctors did not get consent from patients for the sharing of case
reports, but now they have to—and few patients refuse. The risk of exposure from participation in a
trial is way below that of a case report. 
 I'm one of the authors of the paper, and my competing interests areCompeting Interests:
included in the paper.
Discuss this Article
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Author Response (  ) 10 May 2016F1000Research Advisory Board Member
, Patients Know Best Ltd, UKRichard Smith
I’m grateful to Carolyn for commenting on our article, and I agree that “no parties to research are ‘neutral.’”
Indeed, with other colleagues I have written on “the fallacy of impartiality.” (1)
Recognising that nobody, including the authors is neutral, is, as Carolyn writes, a strong argument for data
sharing. She identifies two ways in which we can improve the reliability of research, and they are, of
course, not mutually exclusive—but reanalysis of data may be the best.
1 Smith R, Feachem R, Feachem NS, Koehlmoos TP, Kinlaw H. The fallacy of impartiality: competing
interest bias in academic publications. Journal of the Royal Society of Medicine. 2009;102(2):44-45.
doi:10.1258/jrsm.2009.080400.
 I'm one of the authors of this paper and declared my competing interests in theCompeting Interests:
paper.
Reader Comment 04 May 2016
, Victoria University of Wellington, New ZealandCarolyn Wilshire
"Statisticians say that “if you torture the data they will confess,”
I wish to comment on this quote, which has appeared in various forms in other articles written by they first
author
If we take the quote at face value - to be true in some sense - then it does not raise a problem for data
sharing. Rather, it raises problems with NOT sharing data.
Consider we have a group of primary researchers who collected the data, and another group, who are
suspicious of its conclusions, and wish to examine the data for themselves. Who in this scenario is most
powerfully motivated to "make the data confess"? Very probably, the primary researchers themselves.
Let's be realistic here. Researchers do not approach their data as neutral bystanders without investment.
They come to it with a powerful set of beliefs. Many have invested years of their career into those beliefs.
Like all human beings, they are convinced that there will be support for their view in the data somewhere -
if only they can find it!  So they explore all sort of variables and ways of measuring them. They look at
"outliers" and maybe take a few out in various ways. They notice errors that work against their conclusion,
but may fail to notice those that work in its favour. And so on. These practices are widespread, and need
not indicate outright fraud. But they can - and often do - lead to significant distortion of the facts. Add to
that the personal motives associated with a desire to get published and advance one's career, and we
have the perfect recipe for data torturing.
In Psychology, we are only just becoming aware of the size of this problem, as various findings once
thought to be secure have turned out to be unreplicable.
Page 8 of 9
F1000Research 2016, 5:781 Last updated: 13 JUN 2016
F1000Research
thought to be secure have turned out to be unreplicable.
It is time to recognise that no parties to research are "neutral". All can be subject to bias. There are two
ways to improve the reliability of our research. The first is to continue to question our methods and improve
how we conduct research (through the use of pre-registration, reporting standards and guideline,
consideration of the limits of inferential methods like hull hypothesis testing). The second is to allow groups
with different beliefs and motives to examine the same data. and for each to present their findings.
Researchers can then evaluate both sets of conclusions.
 No competing interests were disclosed.Competing Interests:
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